Breaking News Instant updates and real-time market news.

EVH

Evolent Health

$19.60

0.325 (1.69%)

, CNMD

CONMED

$68.79

0.54 (0.79%)

04:55
05/17/18
05/17
04:55
05/17/18
04:55

BofA/Merrill to hold a conference

Healthcare Conference to be held in Las Vegas on May 15-17.

EVH

Evolent Health

$19.60

0.325 (1.69%)

CNMD

CONMED

$68.79

0.54 (0.79%)

CNC

Centene

$112.98

-0.085 (-0.08%)

MCRB

Seres Therapeutics

$8.81

0.66 (8.10%)

ADRO

Aduro Biotech

$8.30

0.15 (1.84%)

CLVS

Clovis

$51.87

1.12 (2.21%)

ARNA

Arena Pharmaceuticals

$46.57

-0.1 (-0.21%)

AIMT

Aimmune

$29.93

0.08 (0.27%)

ABAX

Abaxis

$83.29

11.41 (15.87%)

LPNT

LifePoint

$55.10

0.15 (0.27%)

AMAG

Amag Pharmaceuticals

$24.00

0.8 (3.45%)

JAZZ

Jazz Pharmaceuticals

$161.11

-1.64 (-1.01%)

GILD

Gilead

$67.53

0.52 (0.78%)

GNMK

GenMark

$6.90

0.3 (4.55%)

HOLX

Hologic

$38.71

0.84 (2.22%)

NVTA

Invitae

$6.48

-0.48 (-6.90%)

BLUE

Bluebird Bio

$178.20

3.45 (1.97%)

ACAD

Acadia

$18.49

-0.08 (-0.43%)

BKD

Brookdale Senior Living

$7.61

0.115 (1.54%)

LLY

Eli Lilly

$81.18

-0.4575 (-0.56%)

MYGN

Myriad Genetics

$34.88

1.07 (3.16%)

  • 17

    May

  • 18

    May

  • 21

    May

  • 21

    May

  • 23

    May

  • 30

    May

  • 31

    May

  • 07

    Jun

  • 12

    Jun

  • 13

    Jun

  • 14

    Jun

  • 14

    Jun

  • 15

    Jun

  • 25

    Jun

  • 26

    Jun

  • 24

    Jul

  • 23

    Oct

  • 14

    Dec

  • 20

    Dec

EVH Evolent Health
$19.60

0.325 (1.69%)

04/24/18
JPMS
04/24/18
DOWNGRADE
Target $17
JPMS
Neutral
Evolent Health assumed with a Neutral from Overweight at JPMorgan
JPMorgan analyst Anne Samuel downgraded Evolent Health to Neutral after assuming lead coverage of the name. The analyst lowered her price target for the shares to $17 from $20. While significant runway remains for the company as healthcare transitions to a new payment model, the current multiple appropriately reflects the modified growth, Samuel tells investors in a research note.
03/14/18
OPCO
03/14/18
NO CHANGE
Target $22
OPCO
Outperform
HHS Secretary comments a 'strong' tailwind for Evolent Health, says Oppenheimer
Oppenheimer analyst Mohan Naidu says that recent rhetoric from the new Health and Human Services Secretary Alex Azar and CMS Administrator Seema Verma makes him believe that the transition toward value-based reimbursement will likely be front and center for the new HHS leadership. The analyst notes that this push will drive more health systems to reconsider their strategy of maintaining the status quo, and to reevaluate and move toward tackling the problems of risk-based reimbursement, which he believes will drive demand for Evolent Health's solutions. Naidu thinks this tailwind will drive pipeline and deal flow for the company, and reiterates an Outperform rating and $22 price target on the stock.
05/14/18
BARD
05/14/18
NO CHANGE
Target $25
BARD
Outperform
Evolent Health investors day very positive, says Baird
Baird analyst Matthew Gillmor called Evolent Health's investors day very positive in that the event reinforced key long-term themes. The analyst said the policy/demand environment seems to be improving and its new client, Lee Health was extremely complimentary of the company's execution. He believes this relationship could expand over time. Gillmor reiterated his Outperform rating and $25 price target on Evolent Health shares.
02/13/18
JEFF
02/13/18
NO CHANGE
Target $22
JEFF
Buy
Evolent remains top idea after management meeting at Jefferies
After meeting with management, Jefferies analyst Sean Dodge says Evolent Health remains one of his top ideas in Healthcare Information Technology. The analyst lowered his price target for the shares to $22 from $28 and keeps a Buy rating on the name. Client decisions have now all been made, giving Evolent good visibility on its mid-/high-teens 2018 revenue outlook, Dodge tells investors in a research note. The analyst believes the company's demand should grow as an increasing proportion of provider reimbursements are tied to quality/value.
CNMD CONMED
$68.79

0.54 (0.79%)

02/13/18
NEED
02/13/18
NO CHANGE
NEED
Needham a buyer of Medical Technologies product makers on Amazon headlines
After The Wall Street Journal report claiming that Amazon (AMZN) is attempting to become a major hospital supplier, Needham analyst Mike Matson said that he believes the e-commerce giant has typically disrupted middlemen much more than manufacturers. The analyst, who thinks Amazon's model may work for "lower tech" products but is unlikely to work with "higher tech" products, would be a buyer of Medical Technologies product maker stocks if they are down on weakness related to the headline risk represented by Amazon. However, Matson notes that he believe that Cantel Medical (CMD), CONMED (CNMD), Medtronic (MDT), Stryker (SYK) and Teleflex (TFX) generate a portion of their sales from "lower tech" products. Other stocks in MedTech manufacturing include AtriCure (ATRI), Cardiovascular Systems (CSII), Hill-Rom (HRC), K2M Group (KTWO), Mazor Robotics (MZOR), Zimmer Biomet (ZBH), Boston Scientific (BSX), Globus Medical (GMED), NuVasive (NUVA) and Wright Medical (WMGI).
02/01/18
NEED
02/01/18
NO CHANGE
Target $71
NEED
Buy
CONMED price target raised to $71 from $58 at Needham
Needham analyst Mike Matson raised his price target on CONMED to $71 and kept his Buy rating after Q4 earnings beat. The analyst says the company has "finally turned around its US Orthopedics business which was the one remaining drag on its growth". Matson also cites the management's forecast of sustaining mid-single digit revenue growth and double-digit EPS growth, which he adds may prove to be conservative.
04/25/18
PIPR
04/25/18
NO CHANGE
Target $61
PIPR
Neutral
CONMED price target raised to $61 from $54 at Piper Jaffray
Piper Jaffray analyst Matt O'Brien raised his price target on CONMED to $61 after the company's Q1 earnings beat, saying the general surgery business was the outperformer in the quarter as "customers are realizing that there is no real comparison to AirSeal" after trialing competitive products. The analyst keeps his Neutral rating on CONMED amid steeper valuation while opting to wait for more evidence of sustained margin expansion.
CNC Centene
$112.98

-0.085 (-0.08%)

03/26/18
BMOC
03/26/18
NO CHANGE
BMOC
Outperform
Centene weakness on NY worries a buying opportunity, says BMO Capital
BMO Capital analyst Matthew Borsch said he would not overreact to a Politico report that Centene's pending acquisition of Fidelis health plan is in jeopardy due to a fight between the Archdiocese of New York and Governor Cuomo. The dispute may impact the deal timing, but both parties have more to gain than lose and he suspects the deal is still substantially more likely than not to get done, Borsch tells investors. The analyst, who said he would be a buyer on any weakness, keeps an Outperform rating on Centene, which he identifies as his favorite name in Managed Care.
02/21/18
PIPR
02/21/18
NO CHANGE
PIPR
Piper sees 'ideal time' to buy Medicaid Managed Care Organizations
Now is an "ideal time" to step in and buy Medicaid Managed Care Organizations Centene (CNC), Molina Healthcare (MOH) and WellCare (WCG), Piper Jaffray analyst Sarah James tells investors in a research note. The stocks are down 12% over the last few weeks due to a combination of the flu and various reform/waiver concerns, the analyst points out. She does not view these as material and says "this is when you double down." Centene is James' top pick.
02/13/18
LEER
02/13/18
NO CHANGE
Target $100
LEER
Market Perform
Centene price target raised to $100 from $90 at Leerink
Leerink analyst Ana Gupte raised her price target for Centene to $100 form $90 saying the Q4 report was "good" and 2018 guidance raise for tax tailwinds was above expectations. The analyst reiterates a Market Perform rating on the shares.
04/11/18
WELS
04/11/18
NO CHANGE
WELS
Centene contract win in Pennsylvania looks set to be rebid, says Wells Fargo
Wells Fargo analyst Peter Costa said he believes the Pennsylvania Commonwealth Court ruled on the side of UnitedHealth (UNH) that the state Department of Human Services violated the state's procurement code when it had previously awarded a Medicaid contract to Centene (CNC). Given this ruling, Costa thinks the state will have to start the procurement process for the third time. He views the court ruling as a modest positive for UnitedHealth and Aetna (AET) and a modest negative for Centene (CNC), though he also noted that this win was not in Centene's 2018 guidance. Costa has Outperform ratings on all three stocks mentioned.
MCRB Seres Therapeutics
$8.81

0.66 (8.10%)

10/12/17
OPCO
10/12/17
INITIATION
Target $19
OPCO
Outperform
Seres Therapeutics initiated with an Outperform at Oppenheimer
Oppenheimer analyst Mark Breidenbach started Seres Therapeutics with an Outperform rating and $19 price target, citing his positive view of the design of the company's Phase 3 SER-109 clinical study and the potential for ecobiotics to secure part of the IBD market.
10/06/17
GHSC
10/06/17
INITIATION
Target $20
GHSC
Buy
Seres Therapeutics initiated with a Buy at Seaport Global
Vernon Bernardino initiated Seres Therapeutics with a Buy and $20 price target.
ADRO Aduro Biotech
$8.30

0.15 (1.84%)

12/13/17
HCWC
12/13/17
NO CHANGE
Target $9.5
HCWC
Buy
Aduro Biotech price target lowered to $9.50 from $18 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis lowered his price target for Aduro Biotech to $9.50 after the company announced the termination of its three CRS-207 clinical studies and discontinuation of the program due to insufficient clinical activity. The analyst believes investors placed limited value to this program after the May 2016 failure of the Phase 2b study in pancreatic cancer. Aduro has a diverse set of candidates in the pipeline which it will place more focus on as a result of CRS-207 based programs being terminated, Pantginis tells investors in a research note. He keeps a Buy rating on Aduro.
02/21/18
CANT
02/21/18
INITIATION
Target $15
CANT
Overweight
Aduro Biotech initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald started Aduro Biotech with an Overweight rating and $15 price target.
02/22/18
02/22/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Loxo Oncology (LOXO) initiated with an Outperform at Oppenheimer. 2. Asterias (AST) initiated with a Buy at B. Riley FBR. 3. Viveve (VIVE) initiated with a Buy at Empire. 4. Panhandle Oil & Gas (PHX) initiated with a Buy at Roth Capital. 5. Aduro Biotech (ADRO) initiated with an Overweight at Cantor Fitzgerald. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/22/18
CANT
02/22/18
INITIATION
Target $15
CANT
Overweight
Cantor likes Aduro's immuno-oncology pipeline, starts at Overweight
Cantor Fitzgerald analyst Mara Goldstein last night initiated Aduro Biotech with an Overweight rating and $15 price target. The analyst likes the company's "broad pipeline," which she believes has the potential to translate into large market opportunities based on several novel immuno-oncology candidates. She expects upcoming catalysts and milestones to expand Aduro's valuation.
CLVS Clovis
$51.87

1.12 (2.21%)

04/09/18
RHCO
04/09/18
NO CHANGE
Target $90
RHCO
Buy
Clovis price target raised to $90 from $85 at SunTrust
SunTrust analyst Peter Lawson raised his price target on Clovis to $90 after the company's Rubraca was approved for second line maintenance therapy in ovarian cancer. Lawson adds that while the approval was "mostly expected", his new price target reflects an increase in the probability of success and deeper conviction for further indicators, while also pointing to a generally broader use of PARP inhibitors. The analyst keeps his Buy rating on Clovis.
02/27/18
LEHM
02/27/18
NO CHANGE
Target $85
LEHM
Overweight
Clovis price target lowered to $85 from $105 at Barclays
Barclays analyst Paul Choi lowered his price target for Clovis Oncology to $85 citing slower market transition to maintenance following the company's Q4 results. The analyst thinks the stock "will likely stay in a holding pattern" prior to the label expansion in the U.S. and an initial treatment indication approval in Europe, both of which are anticipated by Q2. Choi keeps an Overweight rating on Clovis shares.
02/27/18
RHCO
02/27/18
NO CHANGE
Target $85
RHCO
Buy
Clovis price target lowered to $85 from $95 at SunTrust
SunTrust analyst Peter Lawson lowered his price target on Clovis to $85 after the company's Q4 earnings, saying that since the revenues of Rubraca were "essentially flat", the Street was likely to reset growth expectations. The analyst adds that he has pushed back his view of commercialization in prostate and additional settings, but still believes the stock is "attractively positioned with reset revenues, and potentially positive news flows in the near term". Lawson keeps his Buy rating on Clovis.
04/06/18
PIPR
04/06/18
NO CHANGE
PIPR
Neutral
Clovis approval underscores rising competition facing Zejula, says Piper Jaffray
Prior to today's announcement that Clovis' (CLVS) label for its PARP inhibitor Rubraca has been expanded to include maintenance therapy in ovarian cancer, AstraZeneca's (AZN) Lynparza and Tesaro's (TSRO) Zejula were the only two PARP inhibitors approved in the maintenance setting, noted Piper Jaffray analyst Christopher Raymond. While Clovis' approval is not a surprise, it does underscore the intensifying competitive pressure facing Zejula, he said. Raymond, who said PARP inhibitors will primarily be differentiated on safety and added that this does not favor Zejula, keeps a Neutral rating on Tesaro.
ARNA Arena Pharmaceuticals
$46.57

-0.1 (-0.21%)

03/20/18
03/20/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Universal Display (OLED) upgraded to Buy from Hold at Gabelli with analyst Hendi Susanto saying he views the negative market response to a Bloomberg report that Apple (AAPL) is designing and producing MicroLED display prototypes as an overreaction and a buying opportunity. 2. Oneok (OKE) upgraded to Buy from Hold at Jefferies with analyst Christopher Sighinolfi saying he is confident in Oneok's ability to hit target returns on $4.2B of its current projects following a recent meeting with management. 3. PPG (PPG) upgraded to Buy from Hold at Deutsche Bank with analyst David Begleiter saying he believes the company's capital deployment and "valuation discount" are attractive. 4. Roku (ROKU) upgraded to Perform from Underperform at Oppenheimer with analyst Jason Helfstein upgraded Roku (ROKU) to Perform citing valuation and the company's opportunity in virtual multichannel video programming distribution. 5. Arena Pharmaceuticals (ARNA) upgraded to Buy from Hold at Needham with analyst Alan Carr citing the company's "impressive results" from its Phase 2 Ulcerative Colitis study, noting that the the safety and tolerability data components are also "encouraging." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/20/18
JMPS
03/20/18
NO CHANGE
Target $79
JMPS
Outperform
Arena Pharmaceuticals price target raised to $79 from $63 at JMP Securities
JMP Securities analyst Jason Butler said Arena Pharmaceuticals' top-line results for etrasimod in ulcerative colitis meet or beat his best-case expectations and he has increased his view of the probability of success for etrasimod in UC to 75% from 50% following the report of the data. Given the higher odds he places on the success of the drug in that indication, Butler raised his price target on Arena shares to $79 from $63 and keeps an Outperform rating on the stock.
04/19/18
CANT
04/19/18
NO CHANGE
Target $65
CANT
Overweight
Arena's APD371 'another underappreciated asset,' says Cantor Fitzgerald
Cantor Fitzgerald analyst William Tanner views Arena Pharmaceuticals' APD371 in Crohn's abdominal pain as "another underappreciated asset." Release of data from clinical testing is expected in Q2, but is unlikely to have a significant impact on the stock given its early nature, Tanner tells investors in a research note. He believes, however, that APD371's underlying pharmacology could positively position the drug candidate favorably versus other cannabinoid receptor modulators. The analyst raised his price target for the shares to $65 from $64 and keeps an Overweight rating on Arena Pharmaceuticals.
03/21/18
SBSH
03/21/18
NO CHANGE
Target $62
SBSH
Buy
Arena Pharmaceuticals price target raised to $62 from $55 at Citi
Citi analyst Joel Beatty raised his price target for Arena Pharmaceuticals to $62 after the company announced positive Phase 2 topline results for etrasimod in ulcerative colitis. The analyst increased his market penetration projections for etrasimod and maintained a 60% probability of success for the drug. He keeps a Buy rating on Arena Pharmaceuticals.
AIMT Aimmune
$29.93

0.08 (0.27%)

03/27/18
STFL
03/27/18
NO CHANGE
Target $152
STFL
Buy
AnaptysBio price target raised to $152 after peanut allergy data at Stifel
Stifel analyst Alex Schwartz said he believes the Phase IIa ANB020 results reported by AnaptysBio (ANAB) establish proof-of-concept in peanut allergy and he thinks Anaptys can now generate a partnership on more favorable terms to the company. Given that view, he increased ANB020's expected EU royalty rate to 25% from 18% and raised his price target on the stock to $152 from $139. Schwartz added that he believes making direct comparisons to ANB020 to Aimmune's (AIMT) AR101 and DBV Technologies' (DBVT) Viaskin Peanut is difficult as those drugs' mechanism of action, dosing and patient populations are quite different. The analyst keeps a Buy rating on AnaptysBio shares.
04/05/18
PIPR
04/05/18
NO CHANGE
Target $62
PIPR
Overweight
Piper reiterates Overweight on Aimmune after call with allergist
Piper Jaffray analyst Charles Duncan reiterates an Overweight rating on Aimmune Therapeutics (AIMT) with a $62 price target after speaking to a community-based allergist whose practice he feels is representative of the U.S. peanut allergy market. The analyst heard three key takeaways that reinforce his thesis for Aimmune's AR101 market potential: Both safety/tolerability are better than expected and completely feasible in most of his patients, several patient segments will likely prefer AR101 in his practice, and there is likely very high demand for any immunotherapy with community doctors likely to use both AR101 and DBV Technologies' (DBVT) Viaskin, if both are approved.
03/27/18
CANT
03/27/18
NO CHANGE
Target $64
CANT
Overweight
Cantor says AnaptysBio does not look like competition to Aimmune
Cantor Fitzgerald analyst William Tanner says he's "challenged to believe" much more is known about AnaptysBio's (ANAB) ANB020 following last night's peanut allergy data release that involved only 20 patients. In a research note titled "ANB020 Sure Doesn't Look Like AR101 Competition To Us," Tanner reiterates an Overweight rating on Aimmune Therapeutics (AIMT) with a $64 price target. With only two oral food challenges conducted per patient, "it's no wonder there weren't dropouts," the analyst writes.
04/18/18
04/18/18
NO CHANGE
Target $37

Buy
Pediatric allergist sees both DBV, Aimmune winning approval, says Jefferies
Jefferies analyst Eun Yang hosted a discussion panel with a pediatric allergist who believes both both DBV Technologies' (DBVT) Viaskin Peanut and Aimmune's (AIMT) AR101 will be approved by the FDA. The allergist thinks Viaskin would be preferable due to its lower burden of monitoring and AR101 would be preferred due to its stronger efficacy, Yang tells investors in a research note. The doctor believes choice of treatment, if both are approved, will depend on a patients' goal of treatment and preference. Yang has a Buy rating on DBV Technologies with a $37 price target.
ABAX Abaxis
$83.29

11.41 (15.87%)

05/16/18
SIDC
05/16/18
DOWNGRADE
SIDC
Neutral
Abaxis downgraded to Neutral from Buy at Sidoti
01/05/18
NRCS
01/05/18
UPGRADE
NRCS
Buy
Abaxis upgraded to Buy from Neutral at Northcoast
01/09/18
RAJA
01/09/18
UPGRADE
RAJA
Market Perform
Abaxis upgraded to Market Perform from Underperform at Raymond James
05/16/18
FBCO
05/16/18
UPGRADE
FBCO
Neutral
Abaxis upgraded to Neutral from Underperform at Credit Suisse
Credit Suisse analyst Erin Wilson Wright upgraded Abaxis (ABAX) to Neutral citing the takeover by Zoetis (ZTS).
LPNT LifePoint
$55.10

0.15 (0.27%)

03/23/18
MZHO
03/23/18
INITIATION
Target $51
MZHO
Neutral
LifePoint resumed with a Neutral at Mizuho
Mizuho analyst Ann Hynes resumed coverage of LifePoint Health with a Neutral rating and $51 price target.
03/16/18
WOLF
03/16/18
UPGRADE
WOLF
Peer Perform
LifePoint upgraded to Peer Perform from Underperform at Wolfe Research
05/07/18
RHCO
05/07/18
NO CHANGE
Target $58
RHCO
Hold
LifePoint price target raised to $58 from $50 at SunTrust
SunTrust analyst David MacDonald raised his price target on LifePoint to $58 after its "solid" Q1 results along with "in-line EBITDA, OK volumes, and solid cash flow". The analyst notes that the company's "class of 2016" hospitals are seeing expansion and abating labor costs, even though the company's maintained EBITDA forecasts for FY18 are keeping him on the sidelines. MacDonald maintains his Hold rating on LifePoint.
05/14/18
FBCO
05/14/18
NO CHANGE
Target $58
FBCO
Neutral
LifePoint price target raised to $58 from $48 at Credit Suisse
Credit Suisse analyst A.J. Rice raised his price target for LifePoint to $58 from $48 on valuation. The analyst reiterates a Neutral rating on the shares.
AMAG Amag Pharmaceuticals
$24.00

0.8 (3.45%)

05/07/18
PIPR
05/07/18
NO CHANGE
PIPR
Neutral
Amag supply interruptions for Makena could be problematic, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond noted that Amag Pharmaceuticals' 10-Q that was released after the close on Friday included what he believes to be new risk language around supply for Makena's 1mL, single use vial. While similar language was in place in the 10-K, Raymond said the situation appears to have worsened and he thinks this could be "problematic" for the franchise if not resolved soon. He maintains a Neutral rating on Amag shares.
03/14/18
RILY
03/14/18
NO CHANGE
Target $23
RILY
Neutral
Amag Pharmaceuticals price target raised to $23 from $16 at B. Riley FBR
B. Riley FBR analyst David Buck raised his price target for Amag Pharmaceuticals to $23 citing to reflect the high end of guidance adjusted EBITDA estimates and a lack of early-February generic competition to Makena. The analyst, however, keeps a Neutral rating on the shares. He believes Amag's ability to grow beyond 2019 "still depends upon maintaining some tail for Makena."
03/28/18
MSCO
03/28/18
NO CHANGE
MSCO
Overweight
Morgan Stanley says initial formulary coverage for Makena SC looks promising
Morgan Stanley analyst Thomas Smith said his initial channel checks point to solid formulary coverage for Amag's Makena subcutaneous auto-injector, which removes one potential barrier to uptake. The analyst, who believes the durability of the Makena franchise depends largely on the company's ability to execute on the auto-injector launch, keeps an Overweight rating on Amag Pharmaceuticals.
03/23/18
RILY
03/23/18
NO CHANGE
Target $23
RILY
Neutral
Amag settlement mitigates near-term litigation risk, says B. Riley FBR
B. Riley FBR analyst David Buck believes Amag Pharmaceuticals' settlement with Sandoz mitigates the company's litigation risk over the near-term. The agreement, however, may crimp Amag's growth over the longer term, Buck tells investors in an intraday research note. He has a Neutral rating on Amag with a $23 price target.
JAZZ Jazz Pharmaceuticals
$161.11

-1.64 (-1.01%)

05/15/18
WELS
05/15/18
NO CHANGE
WELS
Jazz Pharmaceuticals price target raised to $182 from $176 at Wells Fargo
Wells Fargo analyst David Maris maintained an Outperform rating on Jazz Pharmaceuticals and raised his price target to $182 from $176 on Jazz shares. The analyst also raised his 2018 EPS estimate to $13.00 from $12.91 after Jazz's beat and raise quarter, and raised his outer year Xyrem growth forecasts from 8% to 10% in 2019, from 6% to 8% in 2020 and from 4% to 5% in 2021, based on Xyrem's return to stronger growth in Q1. Maris concluded that he liked " the conservative balance sheet and potential for strategic deals, the current sales trends, and the focus on pipeline progress."
04/12/18
PIPR
04/12/18
NO CHANGE
Target $201
PIPR
Overweight
Jazz remains high conviction specialty pharma idea at Piper Jaffray
After surveying 25 physicians who treat a significant number of obstructive sleep apnea and narcolepsy patients, Piper Jaffray analyst David Amsellem believes peak U.S. sales potential for Jazz Pharmaceuticals' solriamfetol of at least $400M in the OSA/narcolepsy setting is realistic, "particularly given the sizable portion of patients who do not respond adequately to existing options." Solriamfetol helps position Jazz for annual double-digit EBITDA growth over the next several years, Amsellem tells investors in a research note. He calls Jazz one of his highest conviction specialty pharma ideas. The analyst reiterates an Overweight rating on the shares with a $201 price target.
05/01/18
RILY
05/01/18
NO CHANGE
Target $206
RILY
Buy
Jazz Pharmaceuticals named Alpha Generator Pick at B. Riley FBR
B. Riley FBR analyst David Buck named Jazz Pharmaceuticals his Alpha Generator Pick and keeps a Buy rating on the shares with a $206 price target. The analyst views the company's in-line product growth as attractive.
05/01/18
MZHO
05/01/18
NO CHANGE
Target $91
MZHO
Buy
Spark Therapeutics price target raised to $91 from $79 at Mizuho
Mizuho analyst Difei Yang raised her price target for Spark Therapeutics (ONCE) to $91 citing the priority review voucher sale to Jazz Pharmaceuticals (JAZZ) as well as "probability adjusted M&A premium." Spark is one of the highest-quality gene therapy companies, so it is reasonable to apply a conservative takeover premium to the stock's valuation, Yang tells investors in a research note. The analyst reiterates a Buy rating on the shares.
GILD Gilead
$67.53

0.52 (0.78%)

05/02/18
MAXM
05/02/18
NO CHANGE
Target $89
MAXM
Buy
Gilead price target lowered to $89 from $94 at Maxim
Maxim analyst Jason McCarthy lowered his price target on Gilead to $89 after the company's Q1 results missed consensus, driven by lower than expected HIV/HBV revenues. The analyst has also reduced his FY18 EPS view to $6.14 from $6.74 and revenue to $20.5B from $21.4B, adding that while CAR-T treatment is promising, it is still a long way away. McCarthy keeps his Buy rating on Gilead, noting the company's "multiple" catalysts in 2018-2019 along with its $32B cash cushion that can expand the pipeline through M&A.
05/02/18
JEFF
05/02/18
NO CHANGE
Target $95
JEFF
Buy
Gilead turnaround thesis unchanged after Q1 results, says Jefferies
Jefferies analyst Michael Yee says that while Gilead Sciences last night didn't report the best quarter, the turnaround thesis remains unchanged. The results won't prove the thesis to bears, but Gilead's turnaround is underway and should play out over the next four quarters, Yee tells investors in a post-earnings research note. The stock, trading at an 11-12 times price-to-earnings ratio, is "cheap" and the worst is mostly behind the company, Yee adds. He keeps a Buy rating on Gilead with a $95 price target.
05/02/18
LEER
05/02/18
NO CHANGE
Target $72
LEER
Market Perform
Gilead price target lowered to $72 from $80 at Leerink
Leerink analyst Geoffrey Porges lowered his price target for Gilead to $72 from $80 after the company reported Q1 results and produced the first "significant disappointment" of the large cap biotech earnings season. The analyst reiterates a Market Perform rating on the shares.
03/21/18
MSCO
03/21/18
NO CHANGE
Target $209
MSCO
Equal Weight
Bluebird Bio price target to $209 from $152 at Morgan Stanley
Morgan Stanley analyst Matthew Harrison raised his price target on Bluebird Bio (BLUE) to $209 from $152, stating that he now expects BCMA therapies to take 50% of the third line market by 2030 and noting that bb2121 has 50% market share there. The new assumptions increase his peak sales forecast to about $2.6B from about $1B, he pointed out. However, Harrison keeps an Equal Weight rating on Bluebird, stating that he would expect new data to be available at ASCO in June, but would also expect to see competitor data potentially from Celgene's (CELG) Juno, Gilead's (GILD) Kite, Johnson & Johnson's (JNJ) Nanjing Legend and others.
GNMK GenMark
$6.90

0.3 (4.55%)

09/25/17
ADAM
09/25/17
NO CHANGE
ADAM
Genomic Health, Vermillion among 'few winners' after PAMA news, says Canaccord
After the CMS released the proposed 2018 draft Medicare reimbursement rates for clinical lab tests under the Protecting Access to Medicare Act, or PAMA, which marks a major overhaul of Medicare reimbursement for tests, Canaccord analyst Mark Massaro said the cuts were greater than he expected. He identifies the "losers" after the news as LabCorp (LH), Quest Diagnostics (DGX) and GenMark (GNMK) while he sees Genomic Health (GHDX), VeraCyte (VCYT) and Vermillion (VRML) as among the "few winners."
01/08/18
ADAM
01/08/18
NO CHANGE
ADAM
Buy
Week 52 flu data positive for Quidel, GenMark, says Canaccord
Canaccord analyst Mark Massaro said the CDC published its week 52 Influenza Surveillance Report and noted its increase and widespread flu incidence. He is encouraged by the data and now believes there is upside to revenue estimates for both Quidel (QDEL) and GenMark (GNMK). Massaro has a Buy ratings on both stocks, with a $52 price target on Quidel and a $10 price target on GenMark shares.
11/03/17
ADAM
11/03/17
NO CHANGE
Target $10
ADAM
Buy
GenMark price target lowered to $10 from $14 at Canaccord
Canaccord analyst Mark Massaro lowered his price target on GenMark to $10 from $14 following mixed Q3 results. The analyst also has forecasts well below consensus for Q4, citing lower utilization of ePlex placements in Europe and more of a shift to reagent rentals vs. capital placements. Massaro maintained his Buy rating on GenMark shares as he said his long-term thesis remains intact.
11/03/17
RAJA
11/03/17
DOWNGRADE
RAJA
Market Perform
GenMark downgraded to Market Perform from Outperform at Raymond James
Raymond James analyst Nicholas Jansen downgraded GenMark to Market Perform following the negative Q3 report and "sizable" reduction in Q4 guidance. The analyst said the combination of slower-than-anticipated European traction, a shift to more rentals, and delay in the US menu expansion are too much for his "patience to overcome."
HOLX Hologic
$38.71

0.84 (2.22%)

05/03/18
LEER
05/03/18
DOWNGRADE
LEER
Market Perform
Hologic downgraded to Market Perform from Outperform at Leerink
05/03/18
PIPR
05/03/18
NO CHANGE
Target $48
PIPR
Overweight
Hologic weakness today a buying opportunity, says Piper Jaffray
Piper Jaffray analyst William Quirk recommends using today's post-earnings weakness in shares of Hologic as a buying opportunity. He lowered his price target for the stock to $48 from $49 and reiterates an Overweight rating on the name. Hologic lowered its guidance by $40M due largely to CynoSure, Quirk tells investors in a research note. With CynoSure approaching just 10% of the overall business and "seemingly stabilized," longer-term investors can increase Hologic positions for the accelerated organic growth from new product sales, Quirk contends.
05/03/18
05/03/18
DOWNGRADE
Target $41

Market Perform
Hologic downgraded to Market Perform at Leerink
As previously reported, Leerink analyst Richard Newitter downgraded Hologic to Market Perform from Outperform as his conviction in near-term EPS estimate upside has diminished, especially now that its tax-benefit related "EPS cushion" is basically getting used to mitigate Hologic's reduced sales outlook. The analyst also lowered his price target on the shares to $41 from $48.
05/03/18
05/03/18
DOWNGRADE
Target $39

Hold
Hologic downgraded to Hold at Canaccord
As previously reported, Canaccord analyst Mark Massaro downgraded Hologic to Hold from Buy and lowered his price target on the shares to $39 from $48. In a pre-open research note, the analyst said Hologic "has started off on the wrong foot this year, a clear disappointment," and it is unclear to him that resetting the guide changes the fact that Cynosure does not appear to have a near-term catalyst to stabilize the segment, nor does he have conviction it can achieve its goal of double-digit growth anytime soon. Massaro also removed Hologic as one of his top 5 picks for 2018.
NVTA Invitae
$6.48

-0.48 (-6.90%)

08/02/17
AGIS
08/02/17
NO CHANGE
Target $8.33
AGIS
Buy
CombiMatrix deal confusion presents arbitrage opportunity, says Aegis
Aegis analyst Benjamin Haynor noted that SEC filings related to the agreement for CombiMatrix (CBMX) to be acquired by Invitae (NVTA) present two formulas for the calculation of the exchange ratio, which he believes is causing some confusion, creating an arbitrage opportunity. He reiterates his Buy rating on CombiMatrix and raised his price target on the stock to $8.33 from $8.10, adding that the post-announcement rise in Invitae shares may make his target conservative if that move up holds.
08/04/17
LTCO
08/04/17
DOWNGRADE
LTCO
Neutral
CombiMatrix downgraded to Neutral from Buy at Ladenburg
Ladenburg Thalmann analyst Kevin Degeeter downgraded CombiMatrix (CBMX) to Neutral citing the takeover by Invitae (NVTA).
01/05/18
LTCO
01/05/18
INITIATION
Target $15
LTCO
Buy
Invitae initiated with a Buy at Ladenburg
Ladenburg initiated Invitae with a Buy and $15 price target.
BLUE Bluebird Bio
$178.20

3.45 (1.97%)

04/09/18
JEFF
04/09/18
NO CHANGE
JEFF
Jefferies highlights other gene theraphy players after AveXis takeover
Novartis' (NVS) deal to acquire AveXis (AVXS) for $8.7B should remind investors about the ongoing attractiveness within smid-cap biotech, Jefferies analyst Michael Yee tells investors in a research note. Novartis' two large gene therapy deals in four months will lead to a question of "who's next," the analyst adds. Yee says other mid-late stage gene therapy players include Bluebird Bio (BLUE), Spark Therapeutics (ONCE), BioMarin (BMRN), Abeona Therapeutics (ABEO), Regenxbio (RGNX), Nightstar Therapeutics (NITE) and Voyager Therapeutics (VYGR).
04/19/18
RHCO
04/19/18
NO CHANGE
Target $232
RHCO
Buy
Bluebird Bio price target raised to $232 from $223 at SunTrust
SunTrust analyst Edward Nash raised his price target on Bluebird Bio to $232 after yesterday's NEJM publication of interim data from the HGB-204 and HGB-205 studies supporting his belief that "all patients in the HGB-207 study have the potential to achieve transfusion independence". The analyst adds that based on the publication, he has "dialed up his eligible beta-thalassemia patient numbers for LentiGlobil" given the prevalence of beta-thalassemia in the U.S. and E.U. of 15,000 cases, yielding an estimate of addressable market at 7,875 vs. his prior view of 2,650. Nash keeps his Buy rating on Bluebird Bio.
03/28/18
03/28/18
NO CHANGE

Bluebird Bio and Celegene to co-develop bb2121 anti-BMCA therapy
Bluebird Bio (BLUE) and Celgene (CELG) announced that the companies have entered into an agreement to co-develop and co-promote bb2121, an investigational anti-B-cell maturation antigen, or BCMA chimeric antigen receptor, or CAR, T cell therapy for the potential treatment of patients with relapsed/refractory multiple myeloma in the United States.The companies originally entered into a broad, global strategic research collaboration in 2013 to discover, develop and commercialize novel therapies in oncology, which included bb2121.
05/07/18
BERN
05/07/18
NO CHANGE
Target $194
BERN
Market Perform
Bluebird Bio price target lowered to $194 from $211 at Bernstein
Bernstein analyst Vincent Chen lowered his price target for Bluebird Bio to $194 from $211 to reflect increasing operating expenses. The analyst reiterates a Market Perform rating on the shares.
ACAD Acadia
$18.49

-0.08 (-0.43%)

11/06/17
LEER
11/06/17
NO CHANGE
Target $35
LEER
Market Perform
Data suggests Acadia pivotal DRP program is high risk, says Leerink
Following full data from Acadia's phase 2 study of pimavanserin in Alzheimer's Disease Psychosis patients at the Clinical Trials on Alzheimer's Disease, Leerink analyst Paul Matteis says his cautious view on the company's phase 3 dementia related psychosis program remains as the statistically significant benefit for pimavanserin seen at the primary endpoint of 6 weeks was in his view helped considerably by a temporary regression in placebo response, this dynamic was also the case in a featured, more severe subgroup, and dementia related psychosis is a chronic condition, and for any new medication a sustained clinical benefit will be important. He reiterates a Market Perform rating and $35 price target on the shares.
04/10/18
COWN
04/10/18
NO CHANGE
Target $50
COWN
Outperform
Acadia pimavanserin concerns a reason for caution, says Cowen
Cowen analyst Ritu Baral noted yesterday's media report concerning deaths in the Acadia pimavanserin FAERS log. The analyst said based on conversations with key opinion leaders who have major experience with pimavanserin, she thinks there is unlikely a safety signal. However, she does say the concerns keep her cautious on the stock. Baral maintained her Outperform rating and $50 price target on Acadia shares, which dropped 23% to close at $16.50 yesterday.
04/10/18
JPMS
04/10/18
NO CHANGE
Target $50
JPMS
Overweight
Acadia sees little impact from CNN article, says JPMorgan
JPMorgan analyst Cory Kasimov says Acadia Pharmaceuticals management stressed to him their confidence that yesterday's CNN article would have little impact on Nuplazid's commercial prospects. Kasimov says that while management believes the news changes nothing, he worries "that the already tenuous sentiment around the name could have a difficult time withstanding this latest development." It remains to be seen what extent, if any, the creased scrutiny on the safety profile of Nuplazid negatively impacts the product's commercial outlook, Kasimov tells investors in a research note. He believes Acadia'a Q1 earnings report now has even greater significance. The analyst keeps an Overweight rating on Acadia with a $50 price target.
04/26/18
JPMS
04/26/18
NO CHANGE
JPMS
Overweight
JPMorgan still sees low risk of Acadia drug being pulled from market
JPMorgan analyst Cory Kasimov continues to see a low, "but not zero," risk of Acadia Pharmaceuticals' Nuplazid being pulled from the market. Yesterday's CNN report is "mostly noise" and "nothing new," Kasimov told investors last night in a research note. The analyst, however, says he can appreciate the impact of the FDA Commissioner indicating he would "take another look" at the drug's safety profile. Kasimov predicates his views on the formal FDA review and the agency's initial statement that Nuplazid's safety profile is consistent with the label, as well as additional commentary he received yesterday from management. The analyst views yesterday's pullback in shares of Acadia as "fundamentally unjustified based on current information." He kept an Overweight rating on the stock. Shares of Acadia are up 5% to $15.95 in early trading.
BKD Brookdale Senior Living
$7.61

0.115 (1.54%)

02/27/18
RBCM
02/27/18
DOWNGRADE
Target $8
RBCM
Sector Perform
Brookdale Senior Living downgraded to Sector Perform at RBC Capital
As reported earlier, RBC Capital analyst Frank Morgan downgraded Brookdale Senior Living to Sector Perform from Outperform and lowered his price target to $8 from $13 after the company's concluded strategic review yielded a "disappointing outcome". The analyst believes that the strategy to return control to the local level is "reasonable" but will take some time while faced with the "headwinds of increased capacity".
02/27/18
RBCM
02/27/18
DOWNGRADE
RBCM
Sector Perform
Brookdale Senior Living downgraded to Sector Perform at RBC Capital
04/13/18
JMPS
04/13/18
NO CHANGE
Target $9
JMPS
Outperform
Brookdale Senior Living price target lowered to $9 from $16 at JMP Securities
JMP Securities analyst Peter Martin previously valued Brookdale Senior Living on an NAV basis given the expectation of a sale at the conclusion of its strategic alternatives process. While he agrees with the board's decision not to sell the company at depressed levels, he now thinks the board needs to take ownership and that at least three of the four longest tenured board members should resign. He believes 2018 will be another "transitional year" and that weak 2018 guidance is coming and would be patient on an entry point. Martin lowered his price target on Brookdale to $9 from $16, but keeps an Outperform rating on the shares.
04/30/18
BMOC
04/30/18
UPGRADE
Target $53
BMOC
Market Perform
Ventas upgraded to Market Perform at BMO Capital on valuation
As reported earlier, BMO Capital John Kim upgraded Ventas (VTR) to Market Perform from Underperform and raised his price target to $53 from $51. Kim cites a more attractive valuation after the stock price came down another 19% in 2018. The analyst also notes that the extension of Ventas' master lease with Brookdale (BKD) "addresses a major 2019 expiration" and buys time to deal with non-performing assets while also reducing the possibility of a dividend cut in the short term.
LLY Eli Lilly
$81.18

-0.4575 (-0.56%)

04/13/18
04/13/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: Netflix (NFLX) upgraded to Buy from Hold at Deutsche Bank with analyst Bryan Kraft saying he underestimated the market's willingness to underwrite several years of negative free cash flow to drive growth. 2. Eli Lilly (LLY) upgraded to Market Perform from Underperform at BMO Capital with analyst Alex Arfaei saying he believes that his previously expressed concerns around the downside risks for Humalog, cautious outlook for Vernezio, and uncertainty around Bari are "mostly reflected" in the stock, with more balance in risk-reward going forward. 3. Willis Towers Watson (WLTW) upgraded to Buy from Hold at Sandler O'Neill with analyst Paul Newsome saying he is making a valuation call with the stock down to "both absolute and relative valuations that we have not seen since there were significant concerns about the Willis/Towers Watson merger and the company's ability to generate organic growth." 4. Shaw Communications (SJR) upgraded to Buy from Hold at Canaccord and to Outperform from Sector Perform at Scotiabank. 5. eBay (EBAY) upgraded to Buy from Neutral at Monness Crespi with analyst Jim Chartier saying eBay's structured data initiatives have meaningfully improved the eBay marketplace experience for buyers and sellers, resulting in gross merchandise value inflecting to up 7% in the fourth quarter of 2017 from up 1% in the third quarter of 2016. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/23/18
RBCM
04/23/18
NO CHANGE
RBCM
Outperform
Incyte AdCom meeting going more favorably than docs suggested, says RBC Capital
RBC Capital analyst Brian Abrahams said the FDA advisory committee meeting for baricitinib, a rheumatoid arthritis treatment developed by Incyte (INCY) and submitted for review by Eli Lilly (LLY), seems "considerably less negative" than the briefing documents for the meeting had suggested. He sees the tone of the panel and the panelist Q&A suggesting a high likelihood that baricitinib will be approved, with the potential still existing that even a 4mg version could be approved in some form. Abrahams has an Outperform rating and $75 price target on Incyte shares.
04/25/18
DBAB
04/25/18
NO CHANGE
DBAB
Hold
Merck may need to reassess animal health unit, says Deutsche Bank
While Merck (MRK) describes its animal health unit as a key growth driver and an important part of the company, it remains to be seen whether investors will continue to accept this as a reason for the business to remain within the company, Deutsche Bank analyst Gregg Gilbert tells investors in a research note. He believes the unit is potentially undervalued. Given Zoetis' (ZTS) success as a company and a stock, and Eli Lilly's (LLY) ongoing review of strategic options for its Elanco Animal Health business, Gilbert conducted a preliminary separation analysis of Merck's animal health unit. The analysis suggests that a separation could be meaningfully accretive to earnings. The analyst keeps a Hold rating on Merck.
04/13/18
BMOC
04/13/18
UPGRADE
Target $79
BMOC
Market Perform
Eli Lilly upgraded to Market Perform at BMO Capital on valuation
As reported earlier, BMO Capital analyst Alex Arfaei upgraded Eli Lilly to Market Perform from Underperform and raised his price target to $79 from $74. The analyst believes that his previously expressed concerns around the downside risks for Humalog, cautious outlook for Vernezio, and uncertainty around Bari are "mostly reflected" in the stock, with more balance in risk-reward going forward. While he anticipates 2018 to be volatile as maturing diabetes franchise constrains the company's growth plans, Arfaei also sees some tailwinds for Eli Lilly around continued strong growth of Trulicity, further growth of Taltz, Jardiance, and Basglar, as well as potential divestiture of Elanco.
MYGN Myriad Genetics
$34.88

1.07 (3.16%)

03/21/18
MSCO
03/21/18
UPGRADE
MSCO
Equal Weight
Myriad Genetics upgraded to Equal Weight from Underweight at Morgan Stanley
03/21/18
MSCO
03/21/18
UPGRADE
Target $33
MSCO
Equal Weight
Myriad Genetics upgraded to Equal Weight from Underweight at Morgan Stanley
Morgan Stanley analyst Steve Beuchaw upgraded Myriad Genetics to Equal Weight from Underweight based on share price underperformance and improving cancer testing survey share trends. In a research note to investors, the analyst, who has a $33 price target on the shares, said risk/reward is now balanced, given margin trends and reimbursement, upside for new products, while hereditary pricing remains a key downside risk. He added that his fundamental concerns on Myriad , including persisting price pressure in the core hereditary cancer testing franchise, and the expectation that new tests for use in prostate cancer, depression and arthritis will increase at measured paces, are "substantially unchanged."
03/21/18
03/21/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Myriad Genetics (MYGN) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Steve Beuchaw citing share price underperformance and improving cancer testing survey share trends. 2. FedEx (FDX) upgraded to Buy from Hold at Stifel with analyst David Ross saying he likes the company's "general earnings trajectory" following third quarter results. 3. Children's Place (PLCE) upgraded to Buy from Neutral at Citi with analyst Kate McShane saying the company reported another quarter of industry leading comps. 4. Catalent (CTLT) upgraded to Outperform from Market Perform at Raymond James with analyst Michael Baker saying shares are down 15% following the first quarter report on tough second half 2018 comps, and believes shares reflect this dynamic now. 5. WellCare (WCG) upgraded to Outperform from Market Perform at Wells Fargo with analyst Peter Costa saying he believes WellCare could benefit from significantly higher favorable prior period development in 2018. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/13/18
PIPR
03/13/18
NO CHANGE
PIPR
Myriad Genetics subpoena creates overhang, says Piper Jaffray
Piper Jaffray analyst William Quirk believes the subpoena Myriad received from the Health & Human Services Office of the Inspector General is due to one of two issues. First, Myriad performed tests on inappropriate patients, or second, Myriad billed incorrectly.Quirk sees little risk around the first option, but said the second could be more concerning. Regardless of which it is, the analyst said Myriad shares will likely be range-bound until the resolution of the subpoena, and maintained a Neutral rating on Myriad shares.

TODAY'S FREE FLY STORIES

KORS

Michael Kors

$68.63

0.25 (0.37%)

, LULU

Lululemon

$106.18

-0.19 (-0.18%)

11:07
05/26/18
05/26
11:07
05/26/18
11:07
Periodicals
Dollar Tree looks interesting, Barron's says »

Next week, another 20…

KORS

Michael Kors

$68.63

0.25 (0.37%)

LULU

Lululemon

$106.18

-0.19 (-0.18%)

GME

GameStop

$12.64

-0.1 (-0.78%)

DLTR

Dollar Tree

$95.23

0.59 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 31

    May

  • 31

    May

  • 31

    May

  • 12

    Jun

  • 14

    Jun

  • 26

    Jun

KHC

Kraft Heinz

$57.78

0.72 (1.26%)

, QCOM

Qualcomm

$59.95

0.85 (1.44%)

10:58
05/26/18
05/26
10:58
05/26/18
10:58
Periodicals
Kraft Heinz, J&J among safe, 'solid' dividend stocks, Barron's says »

Kraft Heinz (KHC),…

KHC

Kraft Heinz

$57.78

0.72 (1.26%)

QCOM

Qualcomm

$59.95

0.85 (1.44%)

MRK

Merck

$59.08

-0.03 (-0.05%)

TGT

Target

$71.22

0.28 (0.39%)

OMC

Omnicom

$71.98

-0.1 (-0.14%)

CCL

Carnival

$64.27

0.12 (0.19%)

JNJ

Johnson & Johnson

$121.40

0.06 (0.05%)

MMM

3M

$198.98

-0.38 (-0.19%)

LLY

Eli Lilly

$82.75

0.05 (0.06%)

VLO

Valero

$118.81

-3.06 (-2.51%)

EMR

Emerson

$72.50

-0.77 (-1.05%)

WBA

Walgreens Boots Alliance

$63.52

0.09 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 30

    May

  • 30

    May

  • 02

    Jun

  • 04

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 07

    Jun

  • 12

    Jun

  • 19

    Jun

  • 10

    Sep

  • 23

    Oct

MU

Micron

$61.33

-0.15 (-0.24%)

10:48
05/26/18
05/26
10:48
05/26/18
10:48
Periodicals
Micron can solve low valuation, Barron's says »

Micron's stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 20

    Jun

ATUS

Altice USA

$18.50

-0.05 (-0.27%)

10:40
05/26/18
05/26
10:40
05/26/18
10:40
Periodicals
Altice's spinoff could be winning bet, Barron's says »

On June 8, Altice will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 30

    May

MU

Micron

$61.33

-0.15 (-0.24%)

, XLNX

Xilinx

$69.63

0.88 (1.28%)

10:35
05/26/18
05/26
10:35
05/26/18
10:35
Periodicals
AI revolution just getting started, Barron's says »

Artificial Intelligence…

MU

Micron

$61.33

-0.15 (-0.24%)

XLNX

Xilinx

$69.63

0.88 (1.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 20

    Jun

ZTCOY

ZTE Corp.

$0.00

(0.00%)

, DDAIF

Daimler AG

$0.00

(0.00%)

08:08
05/26/18
05/26
08:08
05/26/18
08:08
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

ZTCOY

ZTE Corp.

$0.00

(0.00%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$21.82

-0.445 (-2.00%)

HMC

Honda

$32.04

-0.34 (-1.05%)

NSANY

Nissan

$0.00

(0.00%)

F

Ford

$11.51

-0.11 (-0.95%)

GM

General Motors

$38.30

-0.09 (-0.23%)

TM

Toyota

$129.97

-2.47 (-1.87%)

VLKAY

Volkswagen

$0.00

(0.00%)

BAC

Bank of America

$30.16

-0.03 (-0.10%)

C

Citi

$68.42

-0.86 (-1.24%)

GS

Goldman Sachs

$235.05

-1.1 (-0.47%)

JPM

JPMorgan

$110.62

-0.64 (-0.58%)

MS

Morgan Stanley

$53.02

-0.96 (-1.78%)

USB

U.S. Bancorp

$50.54

-0.14 (-0.28%)

WFC

Wells Fargo

$54.91

0.25 (0.46%)

TWTR

Twitter

$33.64

0.11 (0.33%)

AA

Alcoa

$47.92

-1.26 (-2.56%)

CENX

Century Aluminum

$16.27

-0.07 (-0.43%)

AOBC

American Outdoor Brands

$12.53

0.05 (0.40%)

RGR

Sturm, Ruger

$63.10

0.5 (0.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 30

    May

  • 01

    Jun

  • 06

    Jun

  • 20

    Jun

  • 22

    Jun

  • 13

    Jul

  • 27

    Jul

  • 10

    Sep

  • 12

    Oct

  • 14

    Jan

  • 15

    Apr

  • 15

    Jul

  • 15

    Oct

HCLP

Hi-Crush Partners

$13.20

-0.825 (-5.88%)

17:54
05/25/18
05/25
17:54
05/25/18
17:54
Hot Stocks
Hi-Crush Partners provides update on bulldozer incident in Whitehall facility »

Hi-Crush Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POST

Post Holdings

$77.98

1.49 (1.95%)

17:37
05/25/18
05/25
17:37
05/25/18
17:37
Hot Stocks
Post Holdings reports fire in Michael Foods' plant in Pennsylvania »

Post Holdings reported a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

ABMD

Abiomed

$394.49

0.04 (0.01%)

, WYN

Wyndham

$107.98

-0.58 (-0.53%)

17:34
05/25/18
05/25
17:34
05/25/18
17:34
Hot Stocks
Abiomed to enter S&P 500 index on May 31 »

S&P MidCap 400…

ABMD

Abiomed

$394.49

0.04 (0.01%)

WYN

Wyndham

$107.98

-0.58 (-0.53%)

MSCC

Microsemi

$68.74

0.005 (0.01%)

PRAH

PRA Health

$81.19

0.33 (0.41%)

GME

GameStop

$12.64

-0.1 (-0.78%)

FRED

Fred's

$1.69

0.05 (3.05%)

PRSP

Symbol now PB

$0.00

(0.00%)

RRTS

Roadrunner

$2.19

0.04 (1.86%)

DXC

DXC Technology

$94.20

-5.42 (-5.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 31

    May

  • 05

    Jun

  • 12

    Jun

PRAH

PRA Health

$81.19

0.33 (0.41%)

, ABMD

Abiomed

$394.49

0.04 (0.01%)

17:24
05/25/18
05/25
17:24
05/25/18
17:24
Hot Stocks
Breaking Hot Stocks news story on PRA Health, Abiomed »

PRA Health to replace…

PRAH

PRA Health

$81.19

0.33 (0.41%)

ABMD

Abiomed

$394.49

0.04 (0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 05

    Jun

  • 12

    Jun

WYN

Wyndham

$107.98

-0.58 (-0.53%)

, MSCC

Microsemi

$68.74

0.005 (0.01%)

17:23
05/25/18
05/25
17:23
05/25/18
17:23
Hot Stocks
Breaking Hot Stocks news story on Wyndham, Microsemi »

Wyndham to replace…

WYN

Wyndham

$107.98

-0.58 (-0.53%)

MSCC

Microsemi

$68.74

0.005 (0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABMD

Abiomed

$394.49

0.04 (0.01%)

, WYN

Wyndham

$107.98

-0.58 (-0.53%)

17:21
05/25/18
05/25
17:21
05/25/18
17:21
Hot Stocks
Breaking Hot Stocks news story on Abiomed, Wyndham »

ABIOMED to replace…

ABMD

Abiomed

$394.49

0.04 (0.01%)

WYN

Wyndham

$107.98

-0.58 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 05

    Jun

  • 12

    Jun

PCG

PG&E

$44.67

0.84 (1.92%)

17:16
05/25/18
05/25
17:16
05/25/18
17:16
Periodicals
CA Forestry Dept rules PG&E equipment responsible for wildfires, Bloomberg says »

Report filed by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FARM

Farmer Bros.

$28.50

0.15 (0.53%)

17:09
05/25/18
05/25
17:09
05/25/18
17:09
Hot Stocks
Levin Capital Strategies reports 8.4% stake in Farmer Bros »

Levin Capital purchased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDLS

Noodles & Company

$8.90

-0.35 (-3.78%)

17:07
05/25/18
05/25
17:07
05/25/18
17:07
Syndicate
Breaking Syndicate news story on Noodles & Company »

Noodles & Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$1.22

-0.125 (-9.29%)

17:06
05/25/18
05/25
17:06
05/25/18
17:06
Hot Stocks
Windstream completes one-for-five reverse stock split »

Windstream completed its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDLS

Noodles & Company

$8.90

-0.35 (-3.78%)

17:06
05/25/18
05/25
17:06
05/25/18
17:06
Syndicate
Breaking Syndicate news story on Noodles & Company »

Noodles & Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPD

Enterprise Products

$27.87

-0.12 (-0.43%)

17:01
05/25/18
05/25
17:01
05/25/18
17:01
Hot Stocks
Enterprise Products conduts open season for West Texas Crude oil expansion »

Enterprise Products…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INO

Inovio

$4.89

0.06 (1.24%)

16:37
05/25/18
05/25
16:37
05/25/18
16:37
Syndicate
Breaking Syndicate news story on Inovio »

Inovio files $250M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$10.14

0.13 (1.30%)

16:36
05/25/18
05/25
16:36
05/25/18
16:36
Hot Stocks
Rent-A-Center 16.8% shareholder Engaged Capital nominates Carol McFate to Board »

On May 25, 2018, Engaged…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKER

Akers Biosciences

$0.59

0.0086 (1.48%)

16:34
05/25/18
05/25
16:34
05/25/18
16:34
Hot Stocks
Akers Biosciences receives delinquency notice from NASDAQ »

Akers Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHCP

Ditech

$6.60

0.37 (5.94%)

16:31
05/25/18
05/25
16:31
05/25/18
16:31
Hot Stocks
Ditech discloses receipt of late filing notice from NYSE »

Ditech Holding announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$28.15

-4.82 (-14.62%)

, FL

Foot Locker

$55.97

9.585 (20.67%)

16:30
05/25/18
05/25
16:30
05/25/18
16:30
General news
On The Fly: Top stock stories for Friday »

Stocks on Wall Street…

GPS

Gap

$28.15

-4.82 (-14.62%)

FL

Foot Locker

$55.97

9.585 (20.67%)

HLF

Herbalife Nutrition

$48.76

-5.09 (-9.45%)

IEP

Icahn Enterprises

$69.41

0.22 (0.32%)

FCAU

Fiat Chrysler

$21.82

-0.445 (-2.00%)

DGX

Quest Diagnostics

$105.89

5 (4.96%)

UNH

UnitedHealth

$244.96

2.23 (0.92%)

ROST

Ross Stores

$77.35

-5.6 (-6.75%)

ADSK

Autodesk

$132.80

-5.96 (-4.30%)

AAL

American Airlines

$44.89

1.34 (3.08%)

LUV

Southwest

$52.86

1.65 (3.22%)

DAL

Delta Air Lines

$55.89

1.48 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

  • 30

    May

  • 30

    May

  • 12

    Jun

  • 13

    Jun

  • 14

    Jun

  • 26

    Jun

  • 29

    Jun

16:30
05/25/18
05/25
16:30
05/25/18
16:30
Options
Preliminary option volume of 16.4M today »

Preliminary option volume…

VTL

Vital Therapies

$5.65

-0.475 (-7.76%)

16:26
05/25/18
05/25
16:26
05/25/18
16:26
Syndicate
Breaking Syndicate news story on Vital Therapies »

Vital Therapies files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.